{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:33:14Z","timestamp":1782444794437,"version":"3.54.5"},"reference-count":30,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objectives of this study were to evaluate the safety, plasma and milk pharmacokinetics, excretion in breast milk, and the relative infant dose of ubrogepant following a single oral dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ubrogepant is a calcitonin gene\u2010related peptide receptor antagonist approved for the acute treatment of migraine in adults. Preclinical findings in rats demonstrated comparable concentrations of ubrogepant in milk versus plasma; however, the quantification of ubrogepant excretion in human breast milk and breastfed infant exposure have not been previously evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This open\u2010label, phase 1 study (NCT05892757) enrolled healthy, lactating adult women from July 11, 2023, to February 22, 2024. Participants were 1\u20136\u2009months postpartum and received a single dose of ubrogepant 100\u2009mg (2\u2009\u00d7\u200950\u2009mg tablets) orally. Plasma and breast milk samples were collected for up to 24\u2009h after dosing to evaluate pharmacokinetics and ubrogepant concentrations were determined using validated liquid chromatography tandem mass spectrometry assays. Standard pharmacokinetic parameters were calculated from the plasma concentration and breast milk data using non\u2010compartmental analyses. The milk\u2010to\u2010plasma concentration ratio was calculated based on the ratio of the area under the plasma concentration\u2013time curve from time 0 to infinity (AUC\n                      <jats:sub>\u221e<\/jats:sub>\n                      ) of human milk to the AUC\n                      <jats:sub>\u221e<\/jats:sub>\n                      of plasma. The relative infant dose was calculated as 100 times the quotient of the body weight\u2010normalized infant dose and the body weight\u2010normalized maternal dose. Safety and tolerability were assessed via adverse events, vital signs, electrocardiograms, and clinical laboratory measurements.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 12 women were enrolled who each received a single dose of oral ubrogepant 100\u2009mg. The mean milk\u2010to\u2010plasma ratio was 0.23, the cumulative amount of ubrogepant excreted in breast milk was &lt;0.02% and the calculated relative infant dose was 0.15%. The maximum observed breast milk concentration and AUC of ubrogepant in breast milk were significantly lower (75% and 78%, respectively) compared to plasma. Only two mild adverse events were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Less than 0.02\u2009mg of a 100\u2009mg dose of ubrogepant was excreted in breast milk over a 24\u2010h period. The minimal transfer of ubrogepant into breast milk is not considered clinically relevant.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14960","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T07:23:18Z","timestamp":1747725798000},"page":"1190-1197","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Milk and plasma pharmacokinetics of single\u2010dose ubrogepant in healthy lactating women"],"prefix":"10.1111","volume":"65","author":[{"given":"Ramesh R.","family":"Boinpally","sequence":"first","affiliation":[{"name":"Clinical Pharmacology AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Smith","sequence":"additional","affiliation":[{"name":"Clinical Development AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Cohen","sequence":"additional","affiliation":[{"name":"Pharmacovigilance and Patient Safety AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Trugman","sequence":"additional","affiliation":[{"name":"Former Employee of Clinical Development AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"American Migraine Foundation.Homepage.2023."},{"key":"e_1_2_12_3_1","unstructured":"American Migraine Foundation.Migraine In Women.2023."},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30322-3"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2003.00480.x"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13675"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12728"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1066"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419869918"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1696"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813049"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16711"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01683-5"},{"key":"e_1_2_12_14_1","unstructured":"Center for Drug Evaluation and Research.NDA 211\u2013765 (ubrogepant AGN\u2010241688). Tertiary Pharmacology Review. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211765Orig1s000PharmR.pdfAccessed October 17 2024."},{"key":"e_1_2_12_15_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER).Clinical Lactation Studies: Considerations for Study Design Guidance for Industry.2019."},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/089033402237904"},{"key":"e_1_2_12_17_1","volume-title":"Prescribing Information","author":"UBRELVY (ubrogepant)","year":"2023"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(03)00034-6"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1230197"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.1985.tb00924.x"},{"key":"e_1_2_12_21_1","unstructured":"National Center for Biotechnology Information.PubChem Compound Summary for CID 68748835 Ubrogepant."},{"key":"e_1_2_12_22_1","unstructured":"National Center for Biotechnology Information.PubChem Compound Summary for CID 72163100 Atogepant."},{"key":"e_1_2_12_23_1","unstructured":"National Center for Biotechnology Information.PubChem Compound Summary for CID 51049968 Rimegepant."},{"key":"e_1_2_12_24_1","unstructured":"National Center for Biotechnology Information.PubChem Compound Summary for CID 53472683 Zavegepant."},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-044481981-9\/50021-7"},{"key":"e_1_2_12_26_1","unstructured":"Stanford Medicine Children's Health.Newborn Measurements.2024."},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1089\/bfm.2021.0250"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416653233"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1748-0"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13579"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14960","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T08:44:48Z","timestamp":1762073088000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1111\/head.14960"],"URL":"https:\/\/doi.org\/10.1111\/head.14960","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"2024-11-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}